Plain-English translation of NCT06261346 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether treating donated corneal tissue with plasma rich in growth factors () — a solution made from your own blood — can protect the delicate cells in that tissue during transplant surgery. Researchers want to see if this treatment reduces cell damage after surgery, which could help your transplanted cornea stay healthy longer.
During corneal transplant surgery, the delicate cells lining the back of the donor tissue can be damaged, which may shorten how long the transplant lasts. This trial is testing whether this medication can reduce that damage and help transplants work better for longer.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive corneal transplant surgery as planned — but half of participants will have their donor tissue treated with the growth factor solution before surgery, while the other half will receive standard care. You will then visit the clinic for follow-up appointments over one year to have your eye examined and to check how well your transplant is healing.
AI-generated summary from trial data · Sep 24, 2026 · Not medical advice
United States